news

– Statistically significant difference between ORADUR-Methylphenidate ER Capsule and placebo on SNAP-IV teacher form score – Study drug was generally safe and well tolerated CUPERTINO, Calif., Aug. 8, 2017 /PRNewswire/— DURECT Corporation (Nasdaq: DRRX) today announced that Orient Pharma Co., Ltd., its licensee for certain Asian and South Pacific countries, has informed DURECT that a […]

CUPERTINO, Calif., Aug. 1, 2017 /PRNewswire/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) second quarter 2017 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Tuesday, August 8, 2017 at 4:30 pm Eastern Time (1:30 pm Pacific Time). A live audio webcast

Top-Line Data on Track for Q4 2017 CUPERTINO, Calif., June 22, 2017 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that patient enrollment has been completed in PERSIST, the pivotal Phase 3 clinical trial of POSIMIR® (SABER®-Bupivacaine), an investigational locally acting, non-opioid analgesic intended to provide up to three days of continuous pain relief after

CUPERTINO, Calif., June 19, 2017 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that the previously disclosed development and commercialization agreement with Sandoz AG, a division of Novartis (NYSE: NVS), to develop and market in the United States DURECT’s POSIMIR® (SABER®–Bupivacaine), an investigational locally acting, non-opioid analgesic intended to provide up to three days of

Live Webcast of Earnings Call Today at 4:30 p.m. Eastern Time CUPERTINO, Calif., May 10, 2017 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31, 2017 and provided a corporate update.   Total revenues were $4.6 million and net loss was $8.1 million for the three months ended March

CUPERTINO, Calif., May 8, 2017 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced a development and commercialization agreement with Sandoz AG, a division of Novartis (NYSE: NVS), to develop and market in the United States DURECT’s POSIMIR® (SABER®-Bupivacaine), an investigational locally-acting, non-opioid analgesic intended to provide up to three days of continuous pain relief after

CUPERTINO, Calif., May 4, 2017 /PRNewswire/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) first quarter 2017 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Wednesday, May 10, 2017 at 4:30 pm Eastern Time (1:30 pm Pacific Time). A live audio webcast

Biomarker analysis provides evidence for a potential therapeutic effect of DUR-928 in NASH CUPERTINO, Calif., April 24, 2017 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company actively developing new therapeutics based on its Epigenetic Regulator Program and proprietary drug delivery platforms, announced that clinical data on DUR-928 were presented at The International Liver CongressTM

EASL poster will feature data from a Phase 1b study of DUR-928 in nonalcoholic steatohepatitis (NASH) CUPERTINO, Calif., April 17, 2017 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company actively developing new therapeutics based on its Epigenetic Regulator Program and proprietary drug delivery platforms, announced today that it will present clinical data on DUR-928 at

CUPERTINO, Calif., April 3, 2017 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that Jim Brown, President and Chief Executive Officer, will be presenting at the H.C. Wainwright NASH Investor Conference on Monday, April 3  at 4:40 p.m. Eastern Time.  The conference is being held at the St. Regis Hotel in New York City.  A live